Gilead Reports P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan-hziy) for HR+/HER2- Metastatic Breast Cancer
Shots:
- The company reported the new data from a post hoc subgroup analysis from the P-III (TROPiCS-02) study evaluating Trodelvy vs CT in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and 2 chemotherapies
- The results showed PFS benefits in the ITT population by HER2-IHC status and demonstrated improvement in m-PFS in HER2-low (IHC1+ & IHC2+/ISH-) & IHC0 groups. The results were consistent with (TROPiCS-02) ITT Population & will be presented at ESMO Congress 2022
- The company has submitted an sBLA to the US FDA & the results will be shared with health authorities outside the US. The therapy is also being studied for TNBC & metastatic UC populations along with a range of tumor types
Ref: Businesswire | Image: Gilead
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
